Plus Therapeutics, Inc. (PSTV) — SEC Filings
Plus Therapeutics, Inc. (PSTV) — 50 SEC filings. Latest: 8-K (Apr 9, 2026). Includes 31 8-K, 5 10-Q, 3 DEFA14A.
View Plus Therapeutics, Inc. on SEC EDGAR
Overview
Plus Therapeutics, Inc. (PSTV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 9, 2026: On April 8, 2026, PLUS THERAPEUTICS, INC. filed an 8-K report detailing the departure of a director and the appointment of a new officer. The filing also includes information on compensatory arrangements for certain officers, though specific dollar amounts and names of individuals involved in these
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 7 bearish, 40 neutral, 2 mixed. The dominant filing sentiment for Plus Therapeutics, Inc. is neutral.
Filing Type Overview
Plus Therapeutics, Inc. (PSTV) has filed 31 8-K, 5 10-Q, 3 DEFA14A, 3 DEF 14A, 2 S-1, 1 10-K/A, 2 10-K, 2 S-1/A, 1 SC 13G with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PSTV's 48 recent filings, 8 were flagged as high-risk, 21 as medium-risk, and 19 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.397M |
| Net Income | -$4.423M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $13.289M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- leptomeningeal metastases (LM)
- pediatric brain cancer (PBC)
- recurrent glioblastoma (rGBM)
- Andrew Sims
- David E. Danovitch
- Aaron M. Schleicher
- Marc H. Hedrick, M.D.
- Dr. David J. Bearss
- Mr. David M. Recker
- Mr. Jonathan A. Feeney
Industry Context
PLUS THERAPEUTICS operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for cancer and other life-threatening diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include advancements in targeted therapies, immunotherapy, and personalized medicine, alongside increasing pressure to demonstrate clinical efficacy and cost-effectiveness.
Top Tags
Biotechnology (7) · corporate-governance (6) · financials (6) · filing (5) · SEC Filing (5) · proxy-statement (5) · delisting (5) · 8-K (4) · material-agreement (4) · corporate-action (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $16.673M | Widened from $9.075M in 9M 2024, indicating increased burn rate. |
| Cash and Cash Equivalents | $13.289M | Significant increase from $76K at Dec 31, 2024, due to financing activities. |
| Total Stockholders' Equity | $5.054M | Shifted from a $8.949M deficit at Dec 31, 2024, reflecting capital raises. |
| Research and Development Expenses | $5.438M | Decreased from $8.394M in 9M 2024, potentially impacting drug development pace. |
| Proceeds from Lincoln Park Purchase Agreement | $19.612M | Major contributor to cash increase, but also source of dilution. |
| Common Shares Outstanding | 131,863,969 | Increased from 6,154,758 at Dec 31, 2024, indicating significant dilution. |
| Net Income | $5.151M | For Q2 2025, a swing from a $2.940M loss in Q2 2024, primarily due to derivative gains. |
| Net Cash from Financing | $15.201M | Provided during the six months ended June 30, 2025, bolstering liquidity. |
| Change in Fair Value of Derivative Instruments | $6.512M | Positive impact on Q2 2025 net income. |
| Total Current Liabilities | $7.316M | As of June 30, 2025, a decrease from $15.551M at December 31, 2024. |
| Accumulated Deficit | $505.729M | As of June 30, 2025, indicating significant historical losses. |
| Shares Outstanding | 99,264,526 | As of August 8, 2025, indicating potential dilution. |
| Grant Revenue | $1.390M | For the three months ended June 30, 2025, a slight increase from $1.279M in 2024. |
| Aggregate Grant Support | $25M | Funding for REYOBIQ™ clinical trials, reducing financial burden |
| Year of Key Milestones | 2025 | Completion of ReSPECT-LM safety trial, FDA clearance for pediatric trial, and ongoing ReSPECT-GBM enrollment |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Plus Therapeutics, Inc. (PSTV)?
Plus Therapeutics, Inc. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 31 8-K, 5 10-Q, 3 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PSTV filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 7 bearish, 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Plus Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Plus Therapeutics, Inc. (PSTV) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Plus Therapeutics, Inc.?
Key financial highlights from Plus Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PSTV?
The investment thesis for PSTV includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Plus Therapeutics, Inc.?
Key executives identified across Plus Therapeutics, Inc.'s filings include leptomeningeal metastases (LM), pediatric brain cancer (PBC), recurrent glioblastoma (rGBM), Andrew Sims, David E. Danovitch and 5 others.
What are the main risk factors for Plus Therapeutics, Inc. stock?
Of PSTV's 48 assessed filings, 8 were flagged high-risk, 21 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Plus Therapeutics, Inc.?
Forward guidance and predictions for Plus Therapeutics, Inc. are extracted from SEC filings as they are enriched.